Skip to main content

CUE

Stock

CUE

Stock
Health Care
Biotechnology

Performance overview

CUE Price
Price Chart

Forward-looking statistics

Beta
1.87
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Company info

SectorHealth Care
IndustryBiotechnology
Employees51
Market cap$72.0M

Fundamentals

Enterprise value$44.5M
Revenue$8.0M
Revenue per employee
Profit margin0.00%
Debt to equity108.28

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.64
Dividend per share
Revenue per share$0.13
Avg trading volume (30 day)$204K
Avg trading volume (10 day)$340K
Put-call ratio

Macro factor sensitivity

Growth+2.1
Credit+9.8
Liquidity-1.7
Inflation-0.4
Commodities+0.6
Interest Rates-3.5

Valuation

Dividend yield0.00%
PEG Ratio-1.20
Price to sales6.56
P/E Ratio-1.20
Enterprise Value to Revenue5.57
Price to book6.56

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.25 per share a year ago.

Zacks Investment Research (May 12, 2025)
Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study

Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Interim analysis highlights include: Confirmed partial response (PR) in one patient and stable disease (SD) in five patients, providing early signs of potential single-agent activity of CUE-101.

Benzinga (May 10, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free